I Prayed have prayed
Lord we praise You for this new discovery and we pray that it is the answer to so many prayers for complete healing from cancer.
Reading Time: 2 minutes

Researchers at Cardiff University have discovered a new type of killer T-cell that offers hope of a “one-size-fits-all” cancer therapy.

T-cell therapies for cancer—where immune cells are removed, modified and returned to the patient’s blood to seek and destroy cancer cells—are the latest paradigm in cancer treatments.

The most widely-used therapy, known as CAR-T, is personalized to each patient, but it only targets a few types of cancers and has not been successful for solid tumors, which make up the vast majority of cancers.

Cardiff researchers have now discovered T-cells equipped with a new type of T-cell receptor (TCR) which recognizes and kills most human cancer types, while ignoring healthy cells.

This TCR recognizes a molecule present on the surface of a wide range of cancer cells as well as in many of the body’s normal cells but, remarkably, is able to distinguish between healthy cells and cancerous ones, killing only the latter.

The researchers said this meant it offered “exciting opportunities for pan-cancer, pan-population” immunotherapies not previously thought possible.

How does this new TCR work?

Conventional T-cells scan the surface of other cells to find anomalies and eliminate cancerous cells—which express abnormal proteins—but ignore cells that contain only “normal” proteins.

The scanning system recognizes small parts of cellular proteins that are bound to cell-surface molecules called human leukocyte antigen (HLA), allowing killer T-cells to see what’s occurring inside cells by scanning their surface.

HLA varies widely between individuals, which has previously prevented scientists from creating a single T-cell-based treatment that targets most cancers in all people.

But the Cardiff study, published this week in Nature Immunology, describes a unique TCR that can recognize many types of cancer via a single HLA-like molecule called MR1.

Unlike HLA, MR1 does not vary in the human population—meaning it is a hugely attractive new target for immunotherapies.

What did the researchers show?

T-cells equipped with the new TCR were shown, in the lab, to kill lung, skin, blood, colon, breast, bone, prostate, ovarian, kidney and cervical cancer cells, while ignoring healthy cells.

To test the therapeutic potential of these cells in vivo, the researchers injected T-cells able to recognize MR1 into mice bearing human cancer and with a human immune system.

This showed “encouraging” cancer-clearing results which the researchers said was comparable to the now NHS-approved CAR-T therapy in a similar animal model. . .

What happens next?

Experiments are under way to determine the precise molecular mechanism by which the new TCR distinguishes between healthy cells and cancer.

The researchers believe it may work by sensing changes in cellular metabolism which causes different metabolic intermediates to be presented at the cancer cell surface by MR1.

The Cardiff group hope to trial this new approach in patients towards the end of this year following further safety testing.

Professor Sewell said a vital aspect of this ongoing safety testing was to further ensure killer T-cells modified with the new TCR recognize cancer cells only.

“There are plenty of hurdles to overcome however if this testing is successful, then I would hope this new treatment could be in use in patients in a few years’ time,” he said. . .

(Excerpt from Good News Network.)

Comments (3) Print

Comments

Leave A Reply

Your email address will not be published.

Toni Lynn Lancaster
January 28, 2020

Cancer has taken many of my family. I pray for continuing reasurch,and God be with them in their study.

4
L e
January 28, 2020

Praise God for advancements in science..every good gift comes from above
Bless the Lord and all that is in us bless His Holy name and not forget His benefits..
Who forgives our wrong doings..who heals our diseases..who saves our lives from destruction..
Psalm 103:1-4☝

6
Marty Robinson
January 28, 2020

We do need to be in prayer for the success of this research
and to thank the Lord for all those who work in this endeavor.
This is so amazing; so like God.

4

Partner with Us

Intercessors for America is the trusted resource for millions of people across the United States committed to praying for our nation. If you have benefited from IFA's resources and community, please consider joining us as a monthly support partner. As a 501(c)3 organization, it's through your support that all this possible.

Dave Kubal
IFA President
Become a Monthly Partner

Share

Click below to share this with others

Log in to Join the Conversation

Log in to your IFA account to start a discussion, comment, pray, and interact with our community.